DC

Decheng Capital Portfolio holdings

AUM $732M Turnover 13.33%
1-Year Est. Return 275.56%
This Fund
S&P 500
This Quarter Est. Return
+11.95%
1 Year Est. Return
+275.56%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$422M
AUM Growth
+$95.9M
Cap. Flow
+$72.2M
Cap. Flow %
17.11%
Top 10 Hldgs %
87.52%
Holding
26
New
2
Increased
10
Reduced
2
Closed
–
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.5 years

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$58M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$5.59M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$3.29M
4
LBPH icon
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$1.94M
5
ACLX icon
Arcellx
ACLX
+$1.33M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$1.73M
2
GRAL icon
GRAIL Inc
GRAL
+$128K

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CGON icon
1
CG Oncology
CGON
$5.48B
$207M 48.96%
5,478,810
+20,000
+0.4% +$701K
2024 Q1
2 quarters
NUVB icon
2
Nuvation Bio
NUVB
$1.64B
$59.4M 14.08%
25,954,439
+19,004,200
+273% +$58M
2024 Q2
1 quarter
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$599M
$22.6M 5.35%
1,250,000
+400,000
+47% +$5.59M
2023 Q4
3 quarters
RCUS icon
4
Arcus Biosciences
RCUS
$2.87B
$13.3M 3.15%
869,790
– –
2023 Q4
3 quarters
KRYS icon
5
Krystal Biotech
KRYS
$9.79B
$13.1M 3.09%
71,772
+6,000
+9% +$1.16M
2023 Q4
3 quarters
ILMN icon
6
Illumina
ILMN
$41B
$12.4M 2.93%
94,767
-14,000
-13% -$1.73M
2023 Q4
3 quarters
ZNTL icon
7
Zentalis Pharmaceuticals
ZNTL
$220M
$11.4M 2.71%
3,108,095
+37,653
+1% +$137K
2023 Q4
3 quarters
BYSI icon
8
BeyondSpring
BYSI
$24.1M
$11.4M 2.69%
4,958,143
– –
2023 Q4
3 quarters
NAMS icon
9
NewAmsterdam Pharma
NAMS
$2.39B
$9.79M 2.32%
590,000
+190,000
+48% +$3.29M
2024 Q2
1 quarter
MRUS icon
10
DELISTED
Merus
MRUS
$9.45M 2.24%
189,098
+10,000
+6% +$522K
2024 Q1
2 quarters
MLTX icon
11
MoonLake Immunotherapeutics
MLTX
$863M
$8.4M 1.99%
166,600
– –
2024 Q1
2 quarters
CRNX icon
12
DELISTED
Crinetics Pharmaceuticals
CRNX
$8.07M 1.91%
157,958
– –
2024 Q1
2 quarters
LEGN icon
13
Legend Biotech
LEGN
$3.7B
$5.29M 1.25%
108,558
+10,000
+10% +$533K
2024 Q1
2 quarters
CYTK icon
14
Cytokinetics
CYTK
$8.82B
$4.97M 1.18%
94,043
– –
2024 Q1
2 quarters
AURA icon
15
Aura Biosciences
AURA
$640M
$4.59M 1.09%
515,555
– –
2023 Q4
3 quarters
WGS icon
16
GeneDx Holdings
WGS
$2.05B
$4.4M 1.04%
103,604
– –
2023 Q4
3 quarters
FDMT icon
17
4D Molecular Therapeutics
FDMT
$674M
$4.3M 1.02%
397,835
+50,000
+14% +$830K
2024 Q1
2 quarters
EQ icon
18
Equillium
EQ
$82.4M
$3.7M 0.88%
4,447,308
– –
2023 Q4
3 quarters
VERA icon
19
Vera Therapeutics
VERA
$1.93B
$3.08M 0.73%
69,767
– –
2024 Q2
1 quarter
LBPH icon
20
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.88M 0.44%
+56,350
New +$1.94M
2024 Q3
0 quarters
ACLX icon
21
DELISTED
Arcellx
ACLX
$1.77M 0.42%
21,177
+20,000
+1,699% +$1.33M
2024 Q2
1 quarter
PYXS icon
22
Pyxis Oncology
PYXS
$149M
$1.2M 0.28%
326,810
– –
2023 Q4
3 quarters
ATRC icon
23
AtriCure
ATRC
$2.91B
$751K 0.18%
26,797
– –
2023 Q4
3 quarters
GRAL icon
24
GRAIL Inc
GRAL
$6.24B
$133K 0.03%
9,684
-8,443
-47% -$128K
2024 Q2
1 quarter
RVMD icon
25
Revolution Medicines
RVMD
$41.5B
$90.7K 0.02%
+2,000
New +$87.1K
2024 Q3
0 quarters
1
2

Similar funds

HEIP
Hudson Edge Investment Partners Jersey City, New Jersey $732M AUM 23.32% 1-Year Est. Return
TCP
ThornTree Capital Partners Boston, Massachusetts $731M AUM 30.12% 1-Year Est. Return
MCM
Morton Capital Management Calabasas, California $731M AUM 20.62% 1-Year Est. Return
LS
Liquid Strategies Atlanta, Georgia $732M AUM 17.42% 1-Year Est. Return
MHS
M Holdings Securities Portland, Oregon $731M AUM 34.87% 1-Year Est. Return
MIOT
Massachusetts Institute of Technology Cambridge, Massachusetts $733M AUM 24.57% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $733M AUM 11.32% 1-Year Est. Return
KF
KKM Financial Chicago, Illinois $730M AUM 53.51% 1-Year Est. Return

Decheng Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Decheng Capital held 26 positions worth $422M, up 29% from $326M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Decheng Capital deployed $72.2M of net new capital in Q3 2024, opening 2 new positions and adding to 10 existing holdings. Its largest new stake was Longboard Pharmaceuticals, Inc. Common Stock: 56,350 shares worth $1.88M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Illumina, an estimated $1.73M trimmed.

  • Decheng Capital's largest Q3 2024 buy was Longboard Pharmaceuticals, Inc. Common Stock: 56,350 shares worth $1.88M.
  • Decheng Capital added most to Nuvation Bio in Q3 2024, an estimated $58M increase.
  • Decheng Capital's biggest Q3 2024 reduction was Illumina, cutting an estimated $1.73M.
  • Decheng Capital's ten largest holdings make up 88% of its $422M portfolio in Q3 2024.
  • Decheng Capital opened 2 new positions and closed 0 in Q3 2024.
  • Decheng Capital's portfolio value rose 29% quarter-over-quarter to $422M.

Based on Decheng Capital's 13F filing for Q3 2024, filed 15 Nov 2024.